In last trading session, AstraZeneca PLC (NYSE:AZN) saw 2,214,229 shares changing hands with its beta currently measuring 0.29. Company’s recent per share price level of $52.74 trading at -$0.2 or -0.49% at recent trade assigns it a market valuation of $138.75 Billion. That current price of AZN’s stock is at a discount of -8.91% from its 52-week high price of $57.44 and is indicating a premium of 31.46% from its 52-week low price of $36.15. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 5.82 Million shares which gives us an average trading volume of 5.13 Million if we extend that period to 3-months.
For AstraZeneca PLC (AZN), analysts’ consensus is at an average recommendation of Overweight while assigning it a mean rating of 1.5. Splitting up the data highlights that, out of 25 analysts covering the stock, 3 rated the stock as a Sell while none recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 17 see the stock as a Buy. 2 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of $0.46 in the current quarter.
AstraZeneca PLC (NYSE:AZN) trade information
In the face of being in the red today for losing -0.85%, in the last five days AZN remained trading in the green while hitting it’s week-highest on Tuesday, Jun 23 when the stock touched $55.19- price level, adding 4.71% to its value on the day. AstraZeneca PLC’s shares saw a change of 5.48% in year-to-date performance and have moved -0.81% in past 5-day. AstraZeneca PLC (NYSE:AZN) showed a performance of -0.98% in past 30-days. Number of shares sold short was 3.17 Million shares which calculate 0.62 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $55.32 to the stock, which implies a rise of 4.89% to its current value. Analysts have been projecting $36.6 as a low price target for the stock while placing it at a high target of $65. It follows that stock’s current price would jump +23.25% in reaching the projected high whereas dropping to the targeted low would mean a loss of -30.6% for stock’s current value.
AstraZeneca PLC (AZN) estimates and forecasts
Statistics highlight that AstraZeneca PLC is scoring comparatively higher than the scores of other players of the relevant industry. The company added +6.3% of value to its shares in past 6 months, showing an annual growth rate of 16% while that of industry is 7.9. Apart from that, the company came raising its revenue forecast for fiscal year 2020. The company is estimating its revenue growth to increase by 24.3% in the current quarter and calculating 6% increase in the next quarter. This year revenue growth is estimated to rise 9.1% from the last financial year’s standing.
3 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $6.31 Billion for the same. And 3 analysts are in estimates of company making revenue of $6.9 Billion in the next quarter that will end in September 01, 2020. Company posted $5.82 Billion and $6.41 Billion of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 8.3% while estimating it to be 7.7% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 1% during past 5 years. In 2020, company’s earnings growth rate is likely to be around -39.7% while estimates for its earnings growth in next 5 years are of 18.7%
AstraZeneca PLC is more likely release its next earnings report in July, and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt. With an annual yield of 2.69%, the share has a forward dividend of 1.4 which implies that company’s dividend yield remained growing in trailing twelve months while having a 5 year average dividend yield of 3.98%.
AstraZeneca PLC (NYSE:AZN)’s Major holders
Insiders are in possession of 0% of company’s total shares while institution are holding 18.47% percent of that, with stock having share float percentage of 18.47%. Investors also watch the number of corporate investors in a company very closely, which is 738 institutions for AstraZeneca PLC that are currently holding shares of the company. Wellington Management Company, LLP is the top institutional holder at AZN for having 67.36 Million shares of worth $3.01 Billion. And as of March 30, 2020, it was holding 2.57% of the company’s outstanding shares.
The second largest institutional holder is Primecap Management Company, which was holding about 56.64 Million shares on March 30, 2020. The number of shares represents firm’s hold over 2.16% of outstanding shares, having a total worth of $2.53 Billion.
On the other hand, Vanguard/Wellington Fund Inc. and Vanguard/Primecap Fund are the top two Mutual Funds which own company’s shares. As of February 28, 2020, the former fund manager was holding 28975740 shares of worth $1.27 Billion or 1.1% of the total outstanding shares. The later fund manager was in possession of 28.53 Million shares on March 30, 2020, making its stake of worth around $1.27 Billion in the company or a holder of 1.09% of company’s stock.